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CD4+ T helper 1 cells (Th1) function is closely regulated by an intrinsic developmental program in 47	
which activation/induction and pro-inflammatory interferon (IFN)-g secretion is followed by a 48	
deactivation/contraction period characterized by a switch into co-secretion of immunoregulatory 49	
interleukin (IL)-10. Autocrine intracellular complement (complosome) activity plays a vital role in 50	
Th1 initiation and contraction: T cell receptor (TCR) stimulation induces intracellular activation of 51	
the complement key components C3 (through cathepsin L (CTSL) cleavage) and C5 which leads to 52	
intrinsic engagement of CD46 by C3b, of  the C3a receptor (C3aR) by C3a, and of the C5aR by C5a1,2. 53	
These events mediate the metabolic programming required for IFN-g production and Th1 induction3. 54	
CD46-mediated signals also support subsequent IL-10 switching and Th1 contraction by increasing 55	
oxidative phosphorylation vs. glycolysis ratio, while autocrine C5aR2 engagement by secreted, des-56	
Arginated C5a (C5a-desArg), suppresses intracellular C5aR1 activity (Supplementary Figure 1A 57	
depicts a model summarizing the role of the complosome in Th1 induction and contraction).  58	
Diminished or augmented complosome activation and function is associated with recurrent infections 59	
or hyperactive Th1 responses in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), 60	
respectively4. This raises the possibility that T cell complosome dysregulation may operate in other 61	
immune-mediated rheumatic diseases, such as systemic sclerosis (scleroderma, SSc)5. SSc is a serious 62	
connective tissue disease of unknown etiology characterized by autoimmunity, vasculopathy and 63	
progressive fibrotic changes to major internal organs (skin, lungs, heart, kidneys, gastrointestinal and 64	
musculoskeletal systems).6 Hyperactive T helper cells, often of the Th2 subtype, and increases in IL-65	
6 and/or IL-17-producing CD4+ T cells in the blood and skin of patients have been described 66	
conclusively.6,7,8 However, the evidence for a distinct Th1 involvement is less clear as some 67	
researchers noted augmented Th1 activity while others have failed to observe this. A method to 68	
comprehensively and rapidly monitor complosome activity in cells, however, is currently unavailable: 69	
traditional FACS-based assays generally do not permit measurement of sufficient markers to assess 70	
complosome activity and cellular effector function on a single cell-level. Similarly, RNA-seq or gene 71	
array analyses fail to inform on the intra- or extracellular localization of complement components and 72	
on their protein activation states. Here, we addressed this need for advanced 73	
complosome/complement technologies and generated the first complement-compatible antibody 74	
panel suitable to analyze the complosome signature of cells comprehensively by mass cytometry 75	
(MC, CyTOFÒ) technology. We further utilized this novel MC complosome panel to evaluate CD4+ 76	
T cells isolated from a well-characterised cohort of early-stage treatment-naïve diffuse cutaneous 77	
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systemic sclerosis (dcSSc) for complosome perturbations. This strategy focused on detection of 78	
dysregulation in Th1 induction or contraction in SSc and our results indicate potential biological 79	
coupling of dysregulated complosome activity in a broader range of immune-mediated rheumatic 80	
disease states.  81	
 82	
To assess for a potential defect in Th1 contraction in SSc, we measured cytokine expression from 83	
resting and activated CD4+ T cells isolated from the blood of six dcSSc patients (Patients 1 to 6; 84	
Supplementary Table 1) and matched healthy donors (HDs). Indeed, T cells from these patients not 85	
only displayed significantly increased IL-6 and IL-17 secretion upon CD3+CD46 activation, they 86	
also produced proportionally significantly larger amounts of IFN-g compared to IL-10 with increased 87	
IFN-g:IL-10 ratio without affecting cell viability (Figure 1a and Supplementary Figure 1b and c).  88	
To test our hypothesis that aberrant intracellular complement activity may underpin the reduced 89	
capacity for CD46-mediated Th1 contraction in SSc, we generated and validated a novel mass 90	
cytometry biomarker panel to evaluate complement protein expression and activation states in 91	
unprecedented depth. This panel simultaneously detects a combination of 18 complosome 92	
components (extra- and intracellularly), seven selected T cell markers including those for Th1 and 93	
Th17 activity, four cytokines/effector molecules, and two relevant transcription factors 94	
(Supplementary Table 2). Importantly, this novel antibody panel detects all respective (complement) 95	
antigens in resting or activated T cells in a similar pattern when compared to their ‘conventional’ and 96	
previously published detection patterns via FACS analysis (Supplementary Table 3a-b)1,2. We next 97	
assessed freshly blood-purified and not further activated or CD3+CD46-stimulated CD4+ T cells 98	
isolated from five dcSSc patients (Patients 5 to 9; Supplementary Table 1) utilizing our bespoke MC 99	
panel for complosome activity and functional markers. Data were analyzed using automated 100	
dimension reduction including Uniform Manifold Approximation and Projection (UMAP) or 101	
Stochastic Neighbor Embedding (SNE)  in combination with spanning-tree progression analysis of 102	
density-normalized events (SPADE) for clustering9 as well as deep phenotyping of immune cells10. 103	
We further delineated newly identified relevant cell clusters using our in-house pipeline for cell 104	
clustering (CytoClustr (published8 and available here).   105	
Firstly, UMAP analysis of non-activated T cells isolated from three dcSSc patients (Patient 6, 8 and 106	
9) and three matched HDs revealed a strikingly different single cell complosome 107	
expression/activation landscape between patients and HDs and further a highly complement-enriched 108	
	 3 
island in patients which was absent in HDs (Figure 1b). The identified island was particularly enriched 109	
in C3/C3b, C5/C5b and C5aR1; the three key complosome components that we previously associated 110	
with Th1 (hyper)activity1,2 (Figure 1b). To next assess these complement-enriched cells observed in 111	
the data set in relation to the additional activation, cytokine and transcription factor markers, 112	
normalized FCS expression was Z-scaled, and cells expressing each of C3/C3b, C5/C5b, and C5aR1 113	
at Z>1.96 (p<0.05) were retained and regarded as 'hi' (high in these components). All other cells were 114	
regarded as 'normal'. The expression of all panel markers across these two cell groups, and across 115	
HDs and patients, was cross-analyzed via box and whisker plots (Figure 1c and Supplementary Figure 116	
2a). This analysis  confirmed the presence of a distinct cluster of complement-enriched cells, almost 117	
exclusively in patients but not in HDs (Figure 1c) and further showed that these cells were enriched 118	
for the presence of activated Factor B (Bb Neo), intracellular CD46 and C3aR expression, the 119	
canonical Th1 lineage transcription factor T-bet, and IL-17 (Supplementary Figure 2a). Subsequent 120	
calculation of average expression of markers following viSNE and SPADE, further supported a 121	
substantially altered complosome signature in circulating T cells from these patients (Figure 1d), with 122	
the increased levels of  of intracellular C3a and C5a in patient T cells denoting augmented intracellular 123	
C3 and C5 activation. Patient T cells also express higher intracellular levels of the activating 124	
complement receptors C3aR and C5aR1 whilst the inhibitory receptor C5aR2 is decreased (Figure 125	
1d). Expression of the complement regulator decay accelerating factor (DAF, CD55) is also 126	
augmented, in line with DAF upregulation generally observed on activated T cells, while CD46 shows 127	
a dysregulated isoform expression pattern with a reduction of surface protein expression and an 128	
increase in intracellular presence of the CYT-1-bearing isoform of CD46 (Figure 1d). The latter 129	
indicates likely ongoing autocrine activation of CD46 as CD46 is normally lost on the cell surface 130	
upon stimulation due to metalloprotease-mediated cleavage. A receiver operating curve performed 131	
with pROC package in R and based on markers in Supplementary Figure 2a showed that this specific 132	
complosome signature was able to discriminate patients from HDs (AUC 0.879) (Supplementary Fig. 133	
2b). 134	
We next performed a similar analysis of the patients’ T cells after CD3+CD46 activation and observed 135	
that perturbed complosome activity is further augmented. SPADE analysis to group phenotypically 136	
related cells into clusters using both resting and activated cells confirmed marked differences between 137	
the dcSSc and the HD groups: although CD4+ T cells are evenly distributed within the SPADE tree 138	
prior to stimulation in both dcSSc and HDs cells, cell cluster formation itself is visibly distinct in 139	
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resting cells from dcSSc patients when compared to HDs. CD3+CD46 activation of HD and patient 140	
T cells induced extensive remodeling in both donor groups, and further confirmed that T cells from 141	
patients displayed sustained discrete and more dynamic changes that designate the  majority of their 142	
cells into a distinctive area of the SPADE tree (yellow underlayed area) (Figure 1e). A heatmap 143	
depiction of data derived from activated T cells from HDs and patients (Supplementary Figure 2c) 144	
showed, for example, that the levels of C3a and the activating receptors C3aR and C5aR1 remained 145	
increased, whilst expression of the inhibitory receptor C5aR2 was further reduced when compared to 146	
activated HD T cells (Figure 1e). C5a levels are now reduced in comparison to HD cells, which could 147	
reflect C5a consumption/usage during T cell activation. The negative regulator CD55 showed an 148	
‘ambivalent’ pattern with a clear intracellular decrease cell surface increase on patients’ T cells. 149	
Importantly, the patients’ T cells respond normally to general TCR activation denoted by the expected 150	
increase in CD25, CD28, and CD95 expression, and the concurrent down-regulation of the IL-7 151	
receptor.  152	
Our MC analysis of resting and CD3+CD46 activated T cells from five dcSSc patients indicated that 153	
a shared common feature of their perturbed complosome signature includes (at minimum) augmented 154	
C3 and C5 activation and C5aR1 expression with concurrent reduction in C5aR2 expression (Figure 155	
1b-e). Excitingly, we confirmed via ‘conventional’ FACS analysis that these markers indeed followed 156	
this distinctive pattern in resting CD4+ T cells from two additional dcSSc patients (Patients 10 and 157	
11) (Figure 1f). This indicates that presence of our MC-identified specific complosome signature may 158	
be extended to dcSSc patients across key SSc-hallmark autoantibody specificities. We had previously 159	
shown that reducing CTSL-mediated activation of C3 within T cells through a cell-permeable CTSL 160	
inhibitor normalizes hyperactive Th1 activity in T cells from the synovial fluid of RA patients in 161	
vitro1. CD3+CD46 stimulation of T cells from dcSSc patients in presence of the CTSL inhibitor not 162	
only normalized the IFN-g:IL-10 ratio (Figure 1g) but also significantly reduced IL-6 production 163	
without affecting cell viability (Supplementary Figure 3a and b). In contrast, only C5aR2 agonism 164	
significantly reduced IL-17 expression (Supplementary Figure 3a). TNF-a or IL-4 production in 165	
cultures remained unaltered in HDs and patients’ T cells under any condition assessed, in line with 166	
our previous observations that the complosome is not required for TNF production or Th2 induction 167	
in human CD4+ T cells (Supplementary Figure 3a).  168	
In summary, utilization of our new MC-compatible complosome-specific antibody panel allowed us 169	
to  observe specific perturbations of the complosome in circulating T cells from patients with SSc. 170	
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Importantly, this complosome signature is further exaggerated upon stimulation and remains 171	
distinguishable from those of healthy donors. Thus, biological coupling of perturbed complosome 172	
activity may occur in a wide range of autoimmune rheumatic disease states, including RA, SLE and 173	
SSc. Importantly, this technique/panel can be used to quickly assess other Th1-driven pathologies for 174	
distinct changes in complosome signatures and can be adapted rapidly to probe for in-depth 175	
complosome activity in other cell populations of interest. A refined FACS analysis ‘distilled’ from 176	
such initial exploratory MC complosome screens can then potentially become a tool for early and 177	
easy screening of (T) cell dysregulation in selected patient groups and may provide new biomarkers 178	
for disease stratification. Our results clearly need to be validated in a larger SSc patient cohort and 179	
other rheumatic diseases and we need to gain a better understanding of the diverse activities of the 180	
complosome per se.  181	
 182	
 183	
Figure legend  184	
Figure 1. T cells from patients with diffuse cutaneous scleroderma have reduced capacity for 185	
Th1 contraction and a distinct complosome signature. a Purified blood CD4+ T cells from 186	
treatment-naïve patients newly diagnosed with diffuse cutaneous systemic sclerosis (dcSSc; P1 to 6) 187	
shown a perturbed IFN-g:IL-10 ratio upon activation. b Resting CD4+ T cells from three dcSSc 188	
patients (Patients 6, 8 an 9) and three matched healthy donor (HDs) were stained using the bespoke 189	
MC panel. UMAPs identify patient-specific cell clusters which are enriched in intracellular C5aR1, 190	
C5/C5b and C3/C3b (arrows). c Z-scale cross-analysis of normalized FCS expression from C3/C3b+, 191	
C5/C5b+, and C5aR1+ patient cells (‘hi’) versus all other patient cells ('normal') and HD cells. 192	
Frequencies of complement 'hi' cells and correlation with other markers assessed were calculated and 193	
visualized as a barplot. d Expression summary depicted as heat map of all intracellular and surface 194	
antigens assessed in non-activated T cells dcSSc patients and HDs. Color range indicates relative 195	
expression levels between comparatives (markers) and not absolute values.  e SPADE analysis of data 196	
derived from MC staining of resting and CD3+CD46-activated CD4+ T cells (36 hrs). Cellular 197	
abundance is denoted by node size and internode linkage distance indicates degree of phenotype 198	
relatedness. The level of complosome activity indicated by colors in the side bar. The circumscribed 199	
area contains the population phenotypes that emerge majorly in response to ex vivo stimulation. f 200	
Freshly purified CD4+ T cells from two patients with recent onset dcSSc (Patients 10 and 11) and two 201	
	 6 
matched healthy donors (HDs 10 and 11) were assessed for presence of intracellular C3a, C5a, C5aR1 202	
and C5aR2 by FACS analysis (n = 2). g Purified CD4+ T cells isolated from dcSSc Patients 5, 6, 10, 203	
and 11 and from matched HDs 5, 6, 10, and 11 were CD3+CD46 activated in the presence or absence 204	
of either a cell-permeable cathepsin L inhibitor or a C5aR2 agonist and IFN-g:IL-10 ratio assessed. 205	
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Figure 1: T cells from patients with diffuse cutaneous scleroderma have a perturbed complosome
signature and reduced capacity for Th1 contraction. 
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